糖尿病肾病是1型和2型糖尿病的主要慢性并发症之一,糖尿病肾病的发生及发展中氧化应激等多种因素起重要作用.葡萄糖转运蛋白（glucose protein 2,GLUT2）受到人们的重视,也是因为他可能在糖尿病肾病的发生发展中起着重要作用.本实验探讨...糖尿病肾病是1型和2型糖尿病的主要慢性并发症之一,糖尿病肾病的发生及发展中氧化应激等多种因素起重要作用.葡萄糖转运蛋白（glucose protein 2,GLUT2）受到人们的重视,也是因为他可能在糖尿病肾病的发生发展中起着重要作用.本实验探讨GLUT2在实验性糖尿病大鼠早期肾脏中的变化.展开更多
心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量...心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量负荷、减少心血管死亡及住院风险外,还展现出改善心脏结构和功能、逆转心脏重构的潜力。本文旨在对SGLT2抑制剂在改善心脏重塑方面的研究进展进行综述。Cardiac remodeling, a process of adaptive morphological and structural alterations in the heart triggered by sustained stress, metabolic, and other stimuli, among which pathological cardiac remodeling serves as an independent predictor of adverse cardiovascular outcomes. Recently, novel hypoglycemic agents, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, have emerged as potential therapeutics that not only alleviate volume overload but also reduce the risk of cardiovascular mortality and hospitalization. Additionally, these agents exhibit promising effects in improving cardiac structure and function, as well as reversing pathological cardiac remodeling. This article aims to comprehensively review the progress made in investigating the therapeutic benefits of SGLT2 inhibitors in ameliorating cardiac remodeling.展开更多
文摘心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量负荷、减少心血管死亡及住院风险外,还展现出改善心脏结构和功能、逆转心脏重构的潜力。本文旨在对SGLT2抑制剂在改善心脏重塑方面的研究进展进行综述。Cardiac remodeling, a process of adaptive morphological and structural alterations in the heart triggered by sustained stress, metabolic, and other stimuli, among which pathological cardiac remodeling serves as an independent predictor of adverse cardiovascular outcomes. Recently, novel hypoglycemic agents, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, have emerged as potential therapeutics that not only alleviate volume overload but also reduce the risk of cardiovascular mortality and hospitalization. Additionally, these agents exhibit promising effects in improving cardiac structure and function, as well as reversing pathological cardiac remodeling. This article aims to comprehensively review the progress made in investigating the therapeutic benefits of SGLT2 inhibitors in ameliorating cardiac remodeling.
